TIVA is a method of inducing and maintaining general anaesthesia entirely through intravenous drugs, without using inhaled anaesthetic gases
TIVA is a technique used to induce and maintain general anaesthesia entirely through intravenous drugs, without the use of inhaled anaesthetic gases. It most commonly involves a combination of propofol and remifentanil delivered via syringe pumps and is used across a wide range of surgical specialties.
In the UK and Ireland, general anaesthesia is typically induced using an intravenous bolus of anaesthetic drugs and then maintained with inhaled anaesthetic agents.1 TIVA differs from this conventional approach by maintaining anaesthesia solely through intravenous drug administration throughout the procedure.
Current data suggest that approximately 26% of general anaesthetic cases are maintained using TIVA.2
| TIVA | GA | |
| Equipment needed | Infusion pumps, syringe drivers + IV access | Anaesthetic machine, vaporiser, breathing circuit |
| Environmental Impact | Minimal atmospheric pollution | Volatile gases contribute to greenhouse emissions |
| Common Agents | Propofol, remifentanil, ketamine, Dexmedetomidine + muscle relaxants | Sevoflurane, desflurane, isoflurane + IV induction |
| Route | Intravenous infusion | Vapour inhalation via anaesthetic machine |
| Post-operative Nausea & Vomiting (PONV) | Lower incidence | Higher incidence |
One of the most widely recognised benefits of TIVA is its ability to reduce the incidence of PONV. Affecting up to 27% of surgical patients, PONV can significantly impact patient comfort, delay recovery, and contribute to substantial additional healthcare costs.3
Evidence suggests that TIVA can help lower this risk compared to inhalational anaesthesia. A review of 229 randomised controlled trials involving 20,991 patients found that those receiving TIVA experienced lower rates of PONV than patients whose anaesthesia was maintained using inhaled anaesthetic agents.4
The benefits of TIVA may extend beyond reducing nausea and vomiting. A 2015 study involving 80 women undergoing thyroid surgery compared recovery outcomes between patients receiving TIVA and those whose anaesthesia was maintained using desflurane with remifentanil infusion. Patients in the TIVA group demonstrated significantly improved recovery outcomes, suggesting a more favourable post-operative experience.5
With UK hospitals aiming for around 75% of elective procedures to be performed as day cases, efficient post-operative recovery is an increasingly important consideration.6 As surgical waiting lists continue to place pressure on healthcare systems, reducing recovery times can help improve patient flow, increase bed availability, and support the treatment of more patients.
TIVA has been shown to reduce the time patients spend in the post-anaesthesia care unit (PACU), enabling a faster recovery following surgery. This may be linked to its lower incidence of post-operative nausea and vomiting (PONV) and favourable recovery profile compared to inhalational anaesthesia. As a result, patients may be able to progress more quickly through the recovery pathway and achieve discharge criteria sooner.
In addition, the reduced post-operative discomfort often associated with TIVA may lessen the need for extended monitoring in some patient groups, supporting day-case pathways and helping hospitals work towards their efficiency and discharge targets. By facilitating earlier recovery and discharge, TIVA may contribute to more effective use of healthcare resources while maintaining a positive patient experience.
Effective post-operative pain management plays an important role in patient recovery, influencing mobilisation, comfort, and overall satisfaction following surgery. There is evidence to suggest that TIVA using propofol may provide improved acute post-operative analgesia compared with inhalational anaesthesia, potentially reducing pain in the immediate post-operative period.7
However, the extent of this benefit can vary depending on several factors, including the type of surgical procedure performed and the anaesthetic and analgesic techniques used alongside TIVA.7 While further research is needed to fully understand the relationship between TIVA and post-operative pain control, current evidence indicates that propofol-based TIVA may contribute to a more comfortable recovery for some patients.
Mediplus Dedicated TIVA Sets are meticulously designed in collaboration with anaesthetists to meet the highest standards as outlined by the SIVA, Euro SIVA, and AAGBI guidelines.
TIVA can be performed using a combination of drugs, with the most utilised groups of drugs including hypnotics and short-acting opioids.
Two of the most common drugs are remifentanil and propofol. Propofol has revolutionised IV anaesthesia since it became widely available in the mid-1980s. Usually, there is a relatively rapid and clear-headed recovery it provides patients.1 For this article, the discussion of TIVA will refer mostly to anaesthesia induced and maintained through intravenous infusion.
TIVA can be used for many surgical procedures that require anaesthesia, see below. It is particularly useful when reducing PONV or preserving neurophysiological monitoring is important. However, volatile anaesthesia may still be preferred in some situations, such as severe bronchospasm.
The importance of the perioperative period in cancer metastasis is known, which is why it is important to consider all aspects of surgery when looking at how to improve survival rates, including anaesthesia.
A study comparing the use of volatile anaesthetics and TIVA in oesophageal cancer surgery found that although there was no difference in the cancer recurrence rate between the two, patients who underwent TIVA had a better survival rate.
In the entire cohort, the overall mortality rate during follow-up was 41.4% (382/922) in all patients, 51.3% (98/191) in the VA group, and 36.4% (284/731) in the TIVA group.8
TIVA doesn’t rely on normal pulmonary function to administer active agents. This means that it is well-suited to procedures on the upper airway, allowing for tubeless thoracic surgery.
When compared with general anaesthetic, it has been suggested that TIVA may improve surgical field quality, reduce blood loss and decrease operative time for endoscopic sinus surgery.9
TIVA agents like propofol and remifentanil offer many desirable characteristics that cardiac patients may benefit from, such as improved organ perfusion and protection, modulation of inflammation and brain protection.
TIVA may be recommended for cardiac surgery as when combined with comprehensive target-controlled drug delivery systems that can be adjusted to the specifics of cardiopulmonary bypass, it can be titrated safely and effectively in delicate and sick cardiac patients.10
The main function of anaesthesia in neurosurgery is to provide the patient with stable hemodynamics and reduced cerebral metabolism. Anaesthesia also needs to avoid intracranial hypertension and interfering with intraoperative neuromonitoring. It should also allow for rapid emergence from anaesthesia for neurological examination.11
Volatile anaesthetics (VA) have been shown to affect cerebral autoregulation12 and intracranial pressure13 which may mean that neurosurgery using VA have higher risks such as ischemic cerebral insults.11
Regarding hemodynamic stability, emergence times, extubation times, early cognitive function, and adverse events, TIVA is similar to volatile anaesthetics. However, several prospective, randomised trials suggest that increased intracranial pressure can be decreased while cerebral perfusion can increase in patients who received TIVA during craniotomy procedures.14
Robot-assisted Laparoscopic Radical Prostatectomy (RLRP) usually requires a steep Trendelenburg position and prolonged intraperitoneal carbon dioxide insufflation which results in increased intrabdominal pressure. This is known to cause peritoneal stretching and irritation, which can result in PONV.15
Anaesthesiologists should take additional steps to prevent PONV during RLRPs due to the increased risk of developing it. As mentioned previously, preventing PONV is important for both patients and hospitals.
TIVA has been shown to reduce PONV, with one study investigating its effects in patients undergoing RLRP. In the prospective single-site, double-blinded, randomized, and parallel-arm controlled trial, 62 patients were randomly assigned to the DES or TIVA group. The incidence of nausea in the post-anaesthetic care unit was 22.6% in the DES group and 6.5% in the TIVA (p=0.001) group. The post-operative incidence of nausea at 1-6 hours was 54.8% in the DES group and 16.1% in the TIVA group (p=0.001).15
Obese patients are at increased risk of respiratory complications and postoperative nausea and vomiting (PONV); therefore, the use of TIVA can provide faster and clearer recovery, reduce nausea, and improve respiratory control through the use of short-acting agents, particularly in patients with obstructive sleep apnoea.
In day-case surgery, TIVA supports rapid recovery and early discharge by minimising nausea, reducing postoperative grogginess, and improving overall patient satisfaction.
In orthopaedic surgery, TIVA fits well with enhanced recovery pathways by facilitating early mobilisation, reducing opioid requirements when combined with regional anaesthesia, and preserving neurophysiological monitoring during spinal procedures.
Reducing healthcare-related emissions is becoming an increasingly important priority as hospitals and healthcare systems work towards their sustainability goals. In the United States alone, healthcare is estimated to account for up to 10% of national greenhouse gas emissions.⁵ In the UK, NHS England has committed to achieving net zero carbon emissions by 2050 while continuing to deliver high standards of patient care.
A significant contributor to anaesthesia-related emissions is the use of volatile anaesthetic agents. All volatile anaesthetics are potent greenhouse gases, with global warming potentials (GWPs) ranging from 440 to 6,810 times that of carbon dioxide, which has a reference value of 1. These gases can remain in the atmosphere for extended periods, contributing to their overall environmental impact. For example, nitrous oxide, which is commonly used in clinical practice, has a GWP of 289 and an atmospheric lifetime of approximately 120 years.
As awareness of these environmental impacts grows, some healthcare organisations have taken steps to reduce the use of high-emission anaesthetic agents. Amsterdam University Medical Centre (UMC), for example, has banned the use of nitrous oxide, desflurane, and isoflurane, resulting in a 70% reduction in annual anaesthetic gas canister consumption.17
Because TIVA maintains anaesthesia using intravenous drugs rather than volatile anaesthetic gases, it avoids the direct greenhouse gas emissions associated with inhalational anaesthesia. As a result, TIVA can support hospitals in reducing the environmental footprint of surgical care while continuing to deliver effective anaesthesia for a wide range of procedures.
TIVA and general anaesthesia are considered equally safe when delivered appropriately by trained anaesthetists with standard monitoring. In some situations, TIVA may offer advantages, such as reduced postoperative nausea and vomiting (PONV), smoother recovery, avoidance of malignant hyperthermia-triggering agents, and improved conditions for neurophysiological monitoring. However, it also carries specific risks, including infusion pump failure, accidental interruption of drug delivery, and a potential risk of awareness if not carefully monitored.
TIVA requires reliable intravenous access and the use of syringe drivers or infusion pumps to deliver anaesthetic drugs continuously. Standard anaesthetic monitoring, including ECG, pulse oximetry, capnography, and blood pressure monitoring, is also essential. Airway equipment and oxygen supplies must be immediately available, and depth of anaesthesia monitoring such as BIS is often used to reduce the risk of awareness. In some centres, target-controlled infusion (TCI) pumps are used to allow more precise delivery of intravenous anaesthetic agents.